Merck Serono Board Reshuffle Should Not Dramatically Change Strategic Direction

BMI View: Despite some disappointing verdicts from regulators on promising drug prospects, Merck Serono's long-term strategy - investing in research, embracing personalised medicine, management of a diversified portfolio and aggressively entering emerging markets - is

To read the full article, please choose one of the following options: